Nyzamac Sr (Isosorbide Mononitrate)

Isosorbide Mononitrate, the active ingredient in Nyzamac Sr, is a nitrate presented as an oral tablet for oral use. It is employed to prevent angina pectoris episodes in adult patients with coronary artery disease. The medication provides sustained vasodilation, improving myocardial oxygen supply and reducing the frequency of chest pain attacks.

GNH USA supplies Nyzamac Sr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides reliable logistics for global distribution.

Isosorbide Mononitrate is a long‑acting nitrate used in the management of coronary artery disease. - Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. - Angina prophylaxis during physical exertion: prevents chest pain episodes associated with increased cardiac workload. - Management of angina in patients undergoing stress testing: minimizes ischemic symptoms during diagnostic procedures.

Isosorbide Mononitrate may cause several adverse reactions, ranging from mild to serious.

Common Side Effects: - Headache: throbbing pain often occurring after the first dose. - Dizziness: light‑headed sensation, especially when standing quickly. - Flushing: warmth and redness of the face or neck. - Hypotension: noticeable drop in blood pressure causing weakness.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure reduction that may lead to fainting. - Allergic reactions: rash, itching, swelling or angioedema requiring medical attention.

Before prescribing Nyzamac Sr, clinicians should consider several precautionary measures to ensure safe use. - Blood pressure assessment: verify baseline systolic and diastolic values to avoid excessive hypotension. - Concomitant PDE‑5 inhibitors: avoid co‑administration with sildenafil, tadalafil or similar agents due to risk of severe hypotension. - Orthostatic monitoring: advise patients to rise slowly to reduce dizziness or fainting. - Hepatic impairment: adjust therapy cautiously in patients with moderate to severe liver disease. - Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Isosorbide Mononitrate can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil): may cause profound hypotension. - Rifampin and other strong enzyme inducers: reduce plasma levels and diminish therapeutic effect. - Alcohol: potentiates vasodilatory action, increasing risk of low blood pressure.

Moderate Interactions (Monitor Closely): - Antihypertensive agents (beta‑blockers, ACE inhibitors): additive blood‑pressure‑lowering effect. - Diuretics: may enhance electrolyte disturbances and volume depletion. - Nicorandil: combined nitrate effect can increase risk of severe hypotension.